Drug Trial Radar · NCT05348577
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,035
Actual
Start
Mar 25, 2022
Primary completion
Mar 4, 2026
Study completion Mar 4, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.
Conditions
- Prostate Cancer
Interventions
capivasertibDrug
320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
docetaxelDrug
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
placeboOther
matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in the overall populationTime frame: up to approximately 46 months
- Radiographic Progression-free Survival (rPFS) in the overall populationTime frame: up to approximately 37 months
Locations
217 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Yuma, Arizona
Research Site
Beverly Hills, California
Research Site
Cerritos, California
Research Site
Fresno, California
Research Site
Los Angeles, California
Research Site
Sacramento, California
Research Site
San Francisco, California
Research Site
Santa Barbara, California
Research Site
Santa Monica, California
Research Site
Santa Rosa, California
Research Site
Aurora, Colorado
Research Site
Lakewood, Colorado
Research Site
Littleton, Colorado
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Minneapolis, Minnesota
Research Site
Minneapolis, Minnesota
Research Site
Hackensack, New Jersey
Research Site
Albany, New York
Research Site
The Bronx, New York
Research Site
White Plains, New York
Research Site
Toledo, Ohio
Research Site
Portland, Oregon
Research Site
Bala-Cynwyd, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Greenville, South Carolina
Research Site
Watertown, South Dakota
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Kingwood, Texas
Research Site
San Antonio, Texas
Research Site
Chesapeake, Virginia
Research Site
Seattle, Washington
Research Site
Birtinya, Australia
Research Site
Greenslopes, Australia
Research Site
Kogarah, Australia
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.